Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-28

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Whether preoperative transarterial chemoembolization can prolong survival for the resectable hepatocellular carcinoma remains controversial, particularly in patients with portal vein tumor thrombi. This study designs to systematically identify and summarize the effect of preoperative TACE for resectable HCC with portal venous invasion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis

NCT01350206

Hepatocellular Carcinoma With PVTT

UNKNOWN PHASE4

Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

NCT00646100

Hepatocellular Carcinoma

COMPLETED PHASE4

Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma

NCT00493402

Hepatocellular Carcinoma

COMPLETED PHASE3

Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus

NCT01600196

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

TERMINATED PHASE4

Neo-TACE-HAIC for PVTT-HCC

NCT04181931

Hepatocellular Carcinoma Portal Vein Thrombosis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With various improvements in interventional radiology, since the 2005 practice guidelines issued by the American Association for the Study of Liver Diseases , transcatheter arterial chemoembolization has become one of the available locoregional therapies for HCC. Transcatheter arterial chemoembolization, which generally performed in intermediate-stage HCC patients, involves injection of an embolizing agent into the hepatic artery to deprive the tumor of its major nutrient source via embolization of the nutrient artery, resulting in ischemic necrosis of the tumor. To prevent intrahepatic recurrence due to portal vein invasion of the HCC tumor, therapeutic strategies such as preoperative TACE, and postoperative adjuvant chemotherapy have been tried. According to the latest and the most powerful evidence, however, preoperative TACE is not routinely recommended for patients undergoing hepatectomy to treat resectable HCC , and TACE may delay surgical treatment or decrease the resection volume of the liver, or it also may create a missed opportunity for surgical treatment.

Rather than subject all these patients to such an invasive procedure and put them at risk for missing opportunity for surgical treatment, it may be better to select optimal candidates to receive surgical resection. Recent studies have even shown favorable long-term survival outcomes of HR in well-selected cases of HCC with PVTT. About whether preoperative transarterial chemoembolization is available for the resectable hepatocellular carcinoma with portal vein tumor thrombi, so far, has hardly been reported.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Preoperation TACE arm

In the preoperative TACE arm (Arm 2), patients underwent TACE followed by surgical resection. Preoperative TACE sessions were repeated once at 4-week intervals unless patients showed either PD or PVTT PD. Then, the patients were prepared for surgical resection, with the exception of those with unresectable disease after TACE For patients who had unresectable disease after TACE, plans for surgical resection were abandoned and the subsequent treatment course was determined by his/her attending oncologist

Group Type EXPERIMENTAL

Preoprative TACE

Intervention Type PROCEDURE

Liver resection plus Thrombectomy

Intervention Type PROCEDURE

Liver resection plus Thrombectomy

Resection arm

Liver resection Plus Thrombectomy

Group Type ACTIVE_COMPARATOR

Liver resection plus Thrombectomy

Intervention Type PROCEDURE

Liver resection plus Thrombectomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Preoprative TACE

Intervention Type PROCEDURE

Liver resection plus Thrombectomy

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Preoperative transarterial chemoembolization Removal of all tumor tissue by surgery

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a) age between 18 and 75 years,
* b) HCC with no previous treatment,
* c) the presence of major PVTT or less on imaging,
* d) Eastern Co-operative Group performance status 030 ,
* e) resectable disease

Exclusion Criteria

* a) Child-Pugh class B or C liver cirrhosis, or evidence of hepatic decompensation including ascites, esophageal or gastric variceal bleeding or hepatic encephalopathy, or ICGR-15 \>15%,
* b) an American Society of Anesthesiologists (ASA) score ≥ 3,
* c) the presence of distant metastasis or other malignant diseases

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No